Figure 3
From: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
![Figure 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-015-0568-1/MediaObjects/13058_2015_568_Fig3_HTML.gif)
Univariable hazard ratios for risk of disease recurrence by prognostic factors in centrally confirmed HER2+ placebo patients in TEACH. HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy.